News

January 21, 2021

Data published in Molecular Diagnostics & Therapy demonstrate how Secarna’s powerful bioinformatics generate improved LNA-modified antisense oligonucleotide therapies

January 21, 2021

January 19, 2021

Antisense oligonucleotide candidate derived from Secarna Pharmaceuticals’ LNAplusTM platform has entered pre-clinical safety trials for the treatment of elevated blood lipids

October 13, 2020

Secarna Pharmaceuticals and Denali Therapeutics enter into research and option agreement to develop novel antisense therapies in the field of neurodegenerative diseases

October 13, 2020

August 5, 2020

Secarna Pharmaceuticals and Evotec form strategic partnership in the field of antisense therapy

April 28, 2020

Secarna Pharmaceuticals enters into cooperation with Guangzhou’s Sun Yat-sen University to develop a treatment for SARS-CoV-2 viral infections

April 28, 2020

March 27, 2018

BIO-Europe Spring® 2018 / Secarna MD Jonas Renz on standing out in a crowd